Cancer Research Horizons is a London-based organization dedicated to the development and commercialization of innovations in cancer research. Established in 1982, it serves as a critical connection between academia and industry, leveraging its deep understanding of both sectors to transform promising research into viable commercial solutions that benefit patients while maximizing financial returns. The organization is uniquely positioned to draw on the extensive research and partnerships fostered by its parent entity, Cancer Research UK, the leading charitable funder of cancer research globally. With over 30 years of specialized experience, Cancer Research Horizons has a proven track record in advancing cancer therapeutics, diagnostics, and related technologies. Its team, comprised of experienced and motivated professionals, is divided between drug discovery and commercialization, ensuring a comprehensive approach to delivering breakthrough therapies to patients.
52 North Health is focused on enhancing healthcare for cancer patients, specifically those undergoing chemotherapy, by providing a portable and easy-to-use medical device. This device employs artificial intelligence to assess the risk of neutropenic sepsis, a serious and potentially fatal side effect of chemotherapy. Through a finger prick blood test and a corresponding digital platform, the device measures a patient's neutrophil count and C-reactive protein (CRP) levels at home. This functionality allows for timely identification of patients at risk of sepsis, thereby improving their safety and quality of life. By facilitating rapid management of their condition, 52 North Health offers a reliable and cost-effective solution for cancer patients.
Infinitopes
Seed Round in 2024
Infinitopes is a cancer research organization focused on enhancing the immune system to prevent metastases and ultimately save lives. The company develops healthcare systems and therapeutic designs that integrate advanced tumor target identification technologies with efficient vector delivery systems. By applying this innovative platform in early-stage clinical trials, Infinitopes aims to improve patient outcomes in the fight against cancer and tumors, offering new hope for those affected by these diseases.
Trogenix operates as a therapeutics company, that treats aggressive cancers.
NK:IO
Seed Round in 2023
NK:IO is a biotechnology company focused on advancing natural killer cell-mediated immunotherapy, particularly in the realm of cancer treatment. The company specializes in developing innovative cell therapies and small molecule therapeutics designed to enhance the effectiveness of cancer targeting for physicians. By leveraging cutting-edge research and technology, NK:IO aims to improve treatment outcomes for patients facing cancer.
Elaitra
Pre Seed Round in 2023
Elaitra specializes in advanced breast cancer detection through its innovative digital breast tomosynthesis imaging technology. The company has developed a generative language model for voice-based patient engagement, alongside a unique AI tool that assists healthcare professionals in interpreting 3D X-rays. Elaitra's solutions enhance early detection and diagnosis by providing a viewing assistant and computer-assisted diagnosis for effective triage. With regulatory approvals from the FDA and UK authorities, Elaitra operates in both the United States and the United Kingdom, aiming to improve patient outcomes in breast cancer treatment.
BioCaptiva
Seed Round in 2022
BioCaptiva is a developer of innovative liquid biopsy technology that focuses on the early diagnosis and monitoring of difficult-to-detect cancers. The company's platform is designed to capture circulating free DNA from patients' blood in larger quantities, addressing the limitations commonly associated with current liquid biopsy testing methods. This advancement enables healthcare professionals to explore new approaches for detecting and monitoring various cancers, ultimately aiming to improve patient outcomes through more effective diagnostics.
Achilles Therapeutics
Seed Round in 2016
Achilles Therapeutics Ltd. is a biopharmaceutical company based in London, United Kingdom, focused on developing patient-specific immunotherapies to treat cancer. Founded in 2016, the company creates personalized vaccines and T cell therapies that harness the immune system to target and eliminate cancer cells. By identifying truncal tumor neo-antigens and other cancer-specific markers, Achilles Therapeutics aims to develop next-generation therapies that selectively attack tumors while sparing healthy tissues. Currently, the company is conducting two clinical trials: the CHIRON trial for patients with non-small-cell lung cancer and the THETIS trial for those with recurrent or metastatic melanoma.
GammaDelta Therapeutics
Seed Round in 2016
GammaDelta Therapeutics focuses on developing innovative immunotherapies utilizing gamma delta (γδ) T cells to treat cancer and autoimmune diseases. The company aims to harness the unique properties of tissue resident γδ T cells to enhance the effectiveness of immunotherapy. By leveraging these specialized immune cells, GammaDelta Therapeutics seeks to provide patients with improved treatment options that can significantly impact their health outcomes in the face of serious diseases.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.